Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
10(55.6%)
Early Phase 1
5(27.8%)
N/A
2(11.1%)
Phase 4
1(5.6%)
18Total
Phase 1(10)
Early Phase 1(5)
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT06444022Phase 1Withdrawn

hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT06164288Phase 1Unknown

Safety and Efficacy Study of hAESCs Therapy for aGVHD

Role: lead

NCT03004261Phase 4Completed

CMV-CTL for the Treatment of CMV Infection After HSCT

Role: collaborator

NCT04414813Early Phase 1Completed

Stereotactic Transplantation of hAESCs for Parkinson's Disease

Role: collaborator

NCT02912104Phase 1Completed

A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure

Role: collaborator

NCT05691114Phase 1Recruiting

Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease

Role: collaborator

NCT05435755Early Phase 1Unknown

Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

Role: collaborator

NCT03381807Early Phase 1Unknown

Human Amniotic Epithelial Stem Cell in Treatment of Refractory Severe Intrauterine Adhesion

Role: collaborator

NCT03764228Not ApplicableUnknown

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT03759899Unknown

hAECs Are Preliminarily Applied in Allogeneic Hematopoietic Stem Cell Transplantation

Role: collaborator

NCT04209712Early Phase 1Unknown

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

Role: lead

NCT03223454Phase 1Unknown

Human Amniotic Epithelial Cells for Asherman's Syndrome

Role: collaborator

NCT03207412Not ApplicableUnknown

Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency

Role: collaborator

NCT03031509Phase 1Unknown

Treatment of Nonunion of Limb Fracture With Human Amniotic Epithelial Cells(hAECs)

Role: collaborator

NCT03107975Phase 1Unknown

Effect of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy

Role: collaborator

NCT02961712Phase 1Unknown

Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)

Role: collaborator

NCT02961725Phase 1Unknown

Stem Cells for Treatment of Bronchopleural Fistula

Role: collaborator

NCT02959333Phase 1Unknown

Human Amniotic Epithelial Cells for Treatment of Bronchial Fistula

Role: collaborator

NCT02929797Early Phase 1Unknown

Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer

Role: collaborator

All 19 trials loaded